Source: WASHINGTON STATE UNIVERSITY submitted to NRP
THE STUDY OF IMMUNE RESPONSE TO PATHOGENS USING MONOCLONAL ANTIBODIES
Sponsoring Institution
Agricultural Research Service/USDA
Project Status
ACTIVE
Funding Source
Reporting Frequency
Annual
Accession No.
0442541
Grant No.
(N/A)
Cumulative Award Amt.
(N/A)
Proposal No.
(N/A)
Multistate No.
(N/A)
Project Start Date
Sep 5, 2022
Project End Date
Dec 7, 2022
Grant Year
(N/A)
Program Code
[(N/A)]- (N/A)
Recipient Organization
WASHINGTON STATE UNIVERSITY
240 FRENCH ADMINISTRATION BLDG
PULLMAN,WA 99164-0001
Performing Department
(N/A)
Non Technical Summary
(N/A)
Animal Health Component
20%
Research Effort Categories
Basic
60%
Applied
20%
Developmental
20%
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
3110830109010%
3113310117040%
3113510109030%
3113610117010%
3113999109010%
Goals / Objectives
The Washington State University (WSU) has developed an e vivo platform to characterize the immune response to pathogens or vaccines candidates for the analysis of the elicited cellular immune response, using autologous target cells. This collaborative research project seeks to apply this technique to the analysis of immune response elicited during Foot-and-Mouth Disease Virus (FMDV) infection and after vaccination with the different vaccine platforms currently under investigation at ARS, PIADC.
Project Methods
Using antibodies developed and characterized by WSU Monoclonal Antibody Center, different cell populations from the peripheral blood mononuclear cells (PBMCs), including three different types of antigen-presenting cells (APCs), blood derived dendritic cells (bDCs), monocyte-derived dendritic cells (moDCs) and macrophages (M'), will be isolated and differentiated. Those populations will be used to present the FMDV antigen to stimulate naïve and primed T cells. With newly identified reagents, phenotype and functional activity characterization of different T cells subsets will allow for identification of specific memory or effector CD4 and/or CD8 T cells that proliferate in response to stimulation before and after vaccination and compare response of protected vs non-protected animals. We will use these reagents to characterize the functional activity of memory CD4 helper and CD8 cytotoxic T cells that develop ex vivo following stimulation of PBMCs from vaccinated animals to determine kinetics and quality of the T-cell responses. This will include determining the cytokine expression profile and effector activity of memory CD4 and CD8 T cells proliferating in response to stimulation with antigen primed APC. This technology will be stablished as toolbox to systematically analyze several aspects of the immune response elicited by multiple vaccine platforms currently under development.